CIM Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

CIM Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,743	Closed	-$210K	–	338
2018 Q3	$210K	Sell	10,743 -10,738	-50%	-$204K	0.08%	309
2018 Q2	$356K	Sell	21,481 -10,579	-33%	-$161K	0.12%	246
2018 Q1	$455K	Hold	32,060	–	–	0.15%	188
2017 Q4	$468K	Sell	32,060 -232	-0.7%	-$3.26K	0.16%	180
2017 Q3	$409K	Buy	32,292 +15,705	+95%	+$200K	0.15%	194
2017 Q2	$197K	Sell	16,587 -519	-3%	-$6.46K	0.07%	346
2017 Q1	$253K	Hold	17,106	–	–	0.09%	301
2016 Q4	$277K	Hold	17,106	–	–	0.1%	279
2016 Q3	$310K	Buy	+17,106	New	+$334K	0.12%	240
2015 Q3	–	Sell	-10,742	Closed	-$373K	–	278
2015 Q2	$373K	Sell	10,742 -5,785	-35%	-$177K	0.16%	145
2015 Q1	$429K	Hold	16,527	–	–	0.19%	140
2014 Q4	$213K	Buy	16,527 +2,285	+16%	+$28.6K	0.1%	223
2014 Q3	$175K	Buy	+14,242	New	+$166K	0.09%	192

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CIM Investment Management's HZNP Position: Q4 2018 in Review

CIM Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 10,743 shares — an estimated $210K sold.

CIM Investment Management first reported a position in HZNP in Q3 2014 and held it in 13 quarters. The position peaked at $468K in Q4 2017. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

CIM Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
CIM Investment Management sold 10,743 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $210K.
CIM Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and held it in 13 quarters.
CIM Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $468K in Q4 2017.
239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on CIM Investment Management's 13F filing for Q4 2018, filed 5 Feb 2019.